DDInter257 DDInter596
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myeloma, sarcoma, and pediatric cancers.[A1573,A257614,L45231] However, one of the major side effects of doxorubicin is cardiotoxicity, which excludes patients with poor heart function and requires treatment termination once the maximally tolerated cumulative dose is reached.
Butalbital {u} (Compound) resembles {v} (Compound) Butabarbital
Butabarbital {u} (Compound) causes {v} (Side Effect) Dermatitis exfoliative
Dermatitis exfoliative {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) resembles {v} (Compound) Pentobarbital
Pentobarbital {u} (Compound) downregulates {v} (Gene) TSKU
TSKU {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) resembles {v} (Compound) Secobarbital
Secobarbital {u} (Compound) causes {v} (Side Effect) Feeling abnormal
Feeling abnormal {u} (Side Effect) is caused by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) binds {v} (Gene) CHRNA4
CHRNA4 {u} (Gene) interacts with {v} (Gene) CRELD2
CRELD2 {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) binds {v} (Gene) GABRA1
GABRA1 {u} (Gene) regulates {v} (Gene) KIT
KIT {u} (Gene) is upregulated by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) binds {v} (Gene) GABRA1
GABRA1 {u} (Gene) regulates {v} (Gene) CBR1
CBR1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) binds {v} (Gene) GABRB3
GABRB3 {u} (Gene) regulates {v} (Gene) GABPB1
GABPB1 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Butalbital {u} (Compound) binds {v} (Gene) GABRA5
GABRA5 {u} (Gene) covaries with {v} (Gene) LSM8
LSM8 {u} (Gene) is downregulated by {v} (Compound) Doxorubicin
Butalbital {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Lidocaine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Doxorubicin
Butalbital (Compound) resembles Butabarbital (Compound) and Butabarbital (Compound) causes Dermatitis exfoliative (Side Effect) and Dermatitis exfoliative (Side Effect) is caused by Doxorubicin (Compound)
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxorubicin (Compound)
Butalbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) downregulates TSKU (Gene) and TSKU (Gene) is downregulated by Doxorubicin (Compound)
Butalbital (Compound) resembles Secobarbital (Compound) and Secobarbital (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Doxorubicin (Compound)
Butalbital (Compound) binds CHRNA4 (Gene) and CHRNA4 (Gene) interacts with CRELD2 (Gene) and CRELD2 (Gene) is upregulated by Doxorubicin (Compound)
Butalbital (Compound) binds GABRA1 (Gene) and GABRA1 (Gene) regulates KIT (Gene) and KIT (Gene) is upregulated by Doxorubicin (Compound)
Butalbital (Compound) binds GABRA1 (Gene) and GABRA1 (Gene) regulates CBR1 (Gene) and CBR1 (Gene) is bound by Doxorubicin (Compound)
Butalbital (Compound) binds GABRB3 (Gene) and GABRB3 (Gene) regulates GABPB1 (Gene) and GABPB1 (Gene) is downregulated by Doxorubicin (Compound)
Butalbital (Compound) binds GABRA5 (Gene) and GABRA5 (Gene) covaries with LSM8 (Gene) and LSM8 (Gene) is downregulated by Doxorubicin (Compound)
Butalbital may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Doxorubicin (Compound)